ArticleVeterinary research2025
FtsZ contributes to cytoadhesion and interaction with host extracellular matrix components and plasminogen in Mycoplasma bovis.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mycoplasma bovis causes serious diseases in cattle and is one of the most economically important pathogens threatening the global cattle industry. It is still a great challenge to prevent and control M. bovis infections owing to the increase in antibiotics resistance and unsatisfactorily effective commercial vaccines. FtsZ is commonly considered as a division protein in most bacteria. Owing to the limited genetic manipulation tools of M. bovis, the role of FtsZ in the pathogenicity of M. bovis remains unknown. In this study, FtsZ protein was found to be mainly distributed on the cell membrane, was highly conserved, and had good immunogenicity. FtsZ could bind to embryonic bovine lung cells (EBL) membrane extract, and this binding was inhibited by anti-FtsZ serum. In addition, FtsZ interacted with host extracellular matrix components fibronectin, laminin, vitronectin, and collagen IV in a dose-dependent manner, and promoted tissue diffusion by activating plasminogen through tissue plasminogen activator (tPA). Disruption of the ftsZ gene markedly reduced the adhesion of M. bovis to EBL cells while the complemented strain M. bovis ΔftsZ: ftsZ partly restored the adhesion ability. This is a first description that FtsZ acts as a novel adhesion protein in Mycoplasma, which interacts with host extracellular matrix components and plasminogen, and plays a vital role in adhesion and dissemination. This study expands our understanding of FtsZ significant role in the pathogenicity of M. bovis and provides a new potential vaccine and drug target against M. bovis infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.